Abstract:The core LATS kinases of the Hippo tumor suppressor pathway phosphorylate and inhibit the downstream transcriptional co-activators YAP and TAZ, which are implicated in various cancers. Recent studies have identified various E3 ubiquitin ligases that negatively regulate the Hippo pathway via ubiquitination, yet few deubiquitinating enzymes (DUB) have been implicated. In this study, we report the DUB USP9X is an important regulator of the core kinases of this pathway. USP9X interacted strongly with LATS kinase and to a lesser extent with WW45, KIBRA, and Angiomotin, and LATS co-migrated exclusively with USP9X during gel filtration chromatography analysis. Knockdown of USP9X significantly downregulated and destabilized LATS and resulted in enhanced nuclear translocation of YAP and TAZ, accompanied with activation of their target genes. In the absence of USP9X, cells exhibited an epithelial-to-mesenchymal transition phenotype, acquired anchorage-independent growth in soft agar, and led to enlarged, disorganized, three-dimensional acini. YAP/TAZ target gene activation in response to USP9X knockdown was suppressed by knockdown of YAP, TAZ, and TEAD2. Deletion of USP9X in mouse embryonic fibroblasts resulted in significant downregulation of LATS. Furthermore, USP9X protein expression correlated positively with LATS but negatively with YAP/TAZ in pancreatic cancer tissues as well as pancreatic and breast cancer cell lines. Overall, these results strongly indicate that USP9X potentiates LATS kinase to suppress tumor growth. Cancer Res; 77(18); 4921-33. ©2017 AACR.

The Deubiquitinase USP10 Mediates Crosstalk Between the LKB1/AMPK Axis and Wnt/β-catenin Signaling in Cancer.

LKB1/AMPK axis crosstalks with Wnt/-catenin signaling in cancer via the deubiquitinase USP10

Correction to: USP20 positively regulates tumorigenesis and chemoresistance through β-catenin stabilization

Deubiquitination and Activation of AMPK by USP10.

USP10 strikes down β-catenin by dual-wielding deubiquitinase activity and phase separation potential

USP10 strikes down 8-catenin by dual-wielding deubiquitinase activity and phase separation potential

USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling.

The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization.

USP10 Suppresses Tumor Progression by Inhibiting Mtor Activation in Hepatocellular Carcinoma.

Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway

Deubiquitylase USP9X Suppresses Tumorigenesis by Stabilizing Large Tumor Suppressor Kinase 2 (LATS2) in the Hippo Pathway.

USP10 promotes pancreatic ductal adenocarcinoma progression by attenuating FOXC1 protein degradation to activate the WNT signaling pathway

Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenocarcinoma

Ubiquitin-specific protease 10 determines colorectal cancer outcome by modulating epidermal growth factor signaling via inositol polyphosphate-4-phosphatase type IIB

Beclin1 Controls the Levels of P53 by Regulating the Deubiquitination Activity of USP10 and USP13

Deubiquitinase USP18 Promotes the Progression of Pancreatic Cancer Via Enhancing the Notch1-c-Myc Axis.

The E2F1/USP11 positive feedback loop promotes hepatocellular carcinoma metastasis and inhibits autophagy by activating ERK/mTOR pathway

Deubiquitinase USP9X Deubiquitinates Β-Catenin and Promotes High Grade Glioma Cell Growth

Wnt‐induced deubiquitination FoxM1 ensures nucleus β‐catenin transactivation

USP9X-mediated Deubiquitination of B-cell CLL/lymphoma 9 Potentiates Wnt Signaling and Promotes Breast Carcinogenesis

USP21 deubiquitinase promotes pancreas cancer cell stemness via Wnt pathway activation.